ES2380546T3 - Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma - Google Patents

Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma Download PDF

Info

Publication number
ES2380546T3
ES2380546T3 ES08757088T ES08757088T ES2380546T3 ES 2380546 T3 ES2380546 T3 ES 2380546T3 ES 08757088 T ES08757088 T ES 08757088T ES 08757088 T ES08757088 T ES 08757088T ES 2380546 T3 ES2380546 T3 ES 2380546T3
Authority
ES
Spain
Prior art keywords
amino acid
residue
alkaline phosphatase
sequence
signal peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08757088T
Other languages
English (en)
Spanish (es)
Inventor
Philippe Crine
Guy Boileau
Thomas P. Loisel
Isabelle Lemire
Pierre Leonard
Robert Heft
Hal Landy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enobia Pharma Inc
Enobia Canada LP
Original Assignee
Enobia Pharma Inc
Enobia Canada LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enobia Pharma Inc, Enobia Canada LP filed Critical Enobia Pharma Inc
Application granted granted Critical
Publication of ES2380546T3 publication Critical patent/ES2380546T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/03Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001Alkaline phosphatase (3.1.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
ES08757088T 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma Active ES2380546T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
US917589P 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Publications (1)

Publication Number Publication Date
ES2380546T3 true ES2380546T3 (es) 2012-05-16

Family

ID=40001639

Family Applications (3)

Application Number Title Priority Date Filing Date
ES08757088T Active ES2380546T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES11004496.3T Active ES2471915T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES13002327T Active ES2619332T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES11004496.3T Active ES2471915T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
ES13002327T Active ES2619332T3 (es) 2007-05-11 2008-05-12 Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma

Country Status (25)

Country Link
US (1) US20100297119A1 (enExample)
EP (3) EP2662448B1 (enExample)
JP (1) JP5732603B2 (enExample)
AT (1) ATE536413T1 (enExample)
AU (1) AU2008250945B2 (enExample)
BR (2) BRPI0811198B8 (enExample)
CA (1) CA2687001C (enExample)
CY (1) CY2016005I1 (enExample)
DE (1) DE202008018131U1 (enExample)
DK (3) DK2158319T3 (enExample)
ES (3) ES2380546T3 (enExample)
FR (1) FR16C0007I2 (enExample)
HR (1) HRP20140416T1 (enExample)
HU (2) HUE031655T2 (enExample)
IL (1) IL202057A0 (enExample)
LT (1) LTC2368999I2 (enExample)
LU (1) LU92976I2 (enExample)
ME (1) ME01828B (enExample)
NL (1) NL300798I1 (enExample)
NO (1) NO2016002I2 (enExample)
PL (3) PL2158319T4 (enExample)
PT (3) PT2368999E (enExample)
RS (1) RS53302B (enExample)
SI (2) SI2662448T1 (enExample)
WO (1) WO2008138131A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055861T2 (hu) * 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
EP2185589B1 (en) 2007-06-01 2016-01-06 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
AU2011245005A1 (en) * 2010-04-30 2012-11-22 Alexion Pharma Holding Methods, compositions, and kits for the treatment of matrix mineralization disorders
MX368531B (es) 2010-07-28 2019-10-07 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
CA2823066A1 (en) 2010-12-27 2012-07-05 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
SG11201401605QA (en) * 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2014031646A2 (en) 2012-08-20 2014-02-27 Gliknik Inc. Molecules with antigen binding and polyvalent fc gamma receptor binding activity
PL3097189T3 (pl) 2014-01-24 2018-11-30 Am-Pharma B.V. Chimeryczne białka podobne do alkalicznej fosfatazy
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
MX394116B (es) 2015-07-24 2025-03-19 Gliknik Inc Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
RU2745528C2 (ru) * 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (en) * 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
JP7613826B2 (ja) * 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
WO2018004517A1 (en) 2016-06-27 2018-01-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children and adolescents
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
AU2017371182B2 (en) 2016-12-09 2024-03-28 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
WO2018164995A1 (en) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process
CA3057502A1 (en) * 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
WO2019183209A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
JP2021519590A (ja) * 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ, インコーポレイテッド 糖タンパク質の製造
CN110499284A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Wnt信号通路激活剂在制备治疗基因ALPL敲除小鼠牙硬组织矿化异常产品中的应用
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
JP2021534111A (ja) 2018-08-10 2021-12-09 アレクシオン ファーマシューティカルズ, インコーポレイテッド アルカリホスファターゼを用いて神経線維腫症1型および関連状態を治療する方法
CA3137045A1 (en) 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Alkaline phosphate-based oncology treatments
US12433938B2 (en) * 2019-12-09 2025-10-07 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12478662B2 (en) 2020-01-03 2025-11-25 The United States of America as represented by the Secretary Department of Heath and Human Services TNAP locally administered for promoting periodontal health
WO2022051555A2 (en) * 2020-09-03 2022-03-10 Rampart Bioscience, Inc. Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
AU2022218782A1 (en) 2021-02-12 2023-08-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CA3263089A1 (en) * 2022-08-31 2024-03-07 Univ Utah Res Found GJA1-20K COMPOSITIONS AND METHODS FOR MITIGATING ISCHEMIC-REPERFUSION INJURY

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル. グラハム,フランク 遺伝子治療のためのアデノウイルスベクター
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ,インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ES2284545T3 (es) 1999-11-16 2007-11-16 Genzyme Corporation Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
EP1395293B1 (en) 2001-05-14 2009-07-22 Gbp Ip, Llc Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
US20070081984A1 (en) * 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
BRPI0512496A (pt) 2004-06-23 2008-03-04 Genzyme Corp processos e composições para o tratamento de doenças policìsticas
US20090142347A1 (en) * 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
JP2008521575A (ja) 2004-12-01 2008-06-26 ジェンザイム・コーポレイション 肝臓を標的とした遺伝物質の送達方法

Also Published As

Publication number Publication date
HK1162589A1 (en) 2012-08-31
IL202057A0 (en) 2011-08-01
BR122019000505B1 (pt) 2022-01-18
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
PL2368999T3 (pl) 2014-08-29
BRPI0811198A2 (pt) 2014-10-21
CY2016005I2 (el) 2016-08-31
NL300798I2 (enExample) 2016-03-16
BRPI0811198B1 (pt) 2021-03-09
DE202008018131U1 (de) 2011-12-30
CA2687001A1 (en) 2008-11-20
HK1141047A1 (en) 2010-10-29
PL2662448T3 (pl) 2017-07-31
EP2368999A1 (en) 2011-09-28
NO2016002I1 (no) 2016-02-02
RS53302B (sr) 2014-08-29
DK2368999T3 (da) 2014-05-26
SI2368999T1 (sl) 2014-07-31
WO2008138131A4 (en) 2008-12-31
NO2016002I2 (no) 2016-02-02
WO2008138131A9 (en) 2009-08-06
PL2158319T4 (pl) 2016-04-29
DK2158319T3 (da) 2012-03-19
ME01828B (me) 2014-12-20
NL300798I1 (enExample) 2016-03-16
EP2158319A1 (en) 2010-03-03
ES2471915T3 (es) 2014-06-27
HUS1600005I1 (hu) 2016-02-29
JP2010526543A (ja) 2010-08-05
FR16C0007I1 (enExample) 2016-04-15
HK1191372A1 (en) 2014-07-25
AU2008250945A1 (en) 2008-11-20
BRPI0811198B8 (pt) 2021-05-25
US20100297119A1 (en) 2010-11-25
LTPA2016004I1 (lt) 2016-02-25
EP2158319A4 (en) 2010-07-21
BR122019000505A2 (pt) 2021-12-14
LU92976I2 (en) 2016-04-11
PL2158319T3 (pl) 2012-05-31
PT2662448T (pt) 2017-03-29
SI2662448T1 (sl) 2017-05-31
DK2662448T3 (en) 2017-03-20
EP2662448B1 (en) 2016-12-21
PT2158319E (pt) 2012-03-06
LTC2368999I2 (lt) 2017-09-25
EP2368999B1 (en) 2014-03-12
ES2619332T3 (es) 2017-06-26
WO2008138131A1 (en) 2008-11-20
PT2368999E (pt) 2014-05-26
AU2008250945A2 (en) 2009-12-24
CA2687001C (en) 2019-02-12
BRPI0811198A8 (pt) 2018-08-14
HRP20140416T1 (hr) 2014-06-20
AU2008250945B2 (en) 2013-12-12
CY2016005I1 (el) 2016-08-31
ATE536413T1 (de) 2011-12-15
JP5732603B2 (ja) 2015-06-10
FR16C0007I2 (fr) 2017-01-27
EP2158319B1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
ES2380546T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
US11224638B2 (en) Treating seizure with recombinant alkaline phosphatase
Millán et al. Alkaline phosphatase and hypophosphatasia
Millán et al. Enzyme replacement therapy for murine hypophosphatasia
US9988620B2 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
ES2234032T3 (es) Terapia para la deficiencia de alfa-galactosidasa a.
JP2016504275A (ja) アクチビン−ActRIIアンタゴニスト並びに骨障害及び他の障害の治療に対する使用
ES2796743T3 (es) Un polipéptido de receptor de factor de crecimiento de fibroblastos 3 (FGR3) soluble para su uso en la prevención o tratamiento de trastornos de retraso del crecimiento esquelético
HK1141047B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1162589B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1191372B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
AU2013203875A1 (en) Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof